VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
vTv Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.94+0.40 (+1.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
vTv Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Market Cap | $106.52M | $166.30M |
| Enterprise Value | $19.88M | $87.12M |
| PS Ratio | 2.89 | 3.60 |
| PB Ratio | 1.35 | 2.03 |
| P/TBV Ratio | 1.35 | 2.31 |
Enterprise value
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.54 | 2.43 |
Income (trailing twelve months)
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Revenue | $36.84M | $57.94M |
| Operating Income | -$9.25M | -$21.49M |
| Pretax Income | -$6.40M | -$14.72M |
| Net Income | -$4.76M | -$22.46M |
| EBITDA | -$9.25M | -$17.14M |
Margins
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -25.1% | -44.5% |
| Pretax Margin | -17.4% | -13.0% |
| Profit Margin | -12.9% | -39.2% |
| EBITDA Margin | -25.1% | -31.3% |
Returns
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -11.7% | -53.2% |
| Return on Assets (ROA) | -8.34% | -41.0% |
| Return on Capital Employed (ROCE) | -11.5% | -38.0% |
Growth
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 216600.0% | 6.01% |
Balance sheet
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $86.64M | $62.64M |
| Net Cash (Debt) | $86.64M | $15.77M |
| Net Cash Per Share | $21.91 | $0.66 |
| Equity (Book Value) | $78.63M | $48.61M |
| Book Value Per Share | $19.89 | $1.36 |
| Tangible Book Value | $78.63M | $23.01M |
| Working Capital | $80.57M | $75.09M |
Financial position
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 12.48 | 3.30 |
| Quick Ratio | 12.35 | 2.39 |
Cash flow (trailing twelve months)
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$16.76M | -$12.39M |
Efficiency
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.65 | 0.38 |
| Revenue Per Employee | $1.42M | $398.96K |
| Profits Per Employee | -$182.92K | -$705.27K |
| Employee Count | 26 | 74 |
Dividends and yields
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -4.46% | -22.8% |
Shares
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 3,954,020 | 58,139,000 |
| Float | 2,914,110 | 49,154,900 |
| Shares Held by Insiders | 26.3% | 11.6% |
| Shares Held by Institutions | 40.6% | 59.4% |
Taxes
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $89.00K |
Scores
| Measure | vTv Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 3.26 | -0.27 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from vTv Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.